tyrosyl-arginyl-phenylalanyl-sarcosine has been researched along with morphine in 1 studies
| Studies (tyrosyl-arginyl-phenylalanyl-sarcosine) | Trials (tyrosyl-arginyl-phenylalanyl-sarcosine) | Recent Studies (post-2010) (tyrosyl-arginyl-phenylalanyl-sarcosine) | Studies (morphine) | Trials (morphine) | Recent Studies (post-2010) (morphine) |
|---|---|---|---|---|---|
| 15 | 0 | 1 | 44,270 | 5,200 | 8,695 |
| Protein | Taxonomy | tyrosyl-arginyl-phenylalanyl-sarcosine (IC50) | morphine (IC50) |
|---|---|---|---|
| Delta-type opioid receptor | Mus musculus (house mouse) | 0.2939 | |
| Delta-type opioid receptor | Rattus norvegicus (Norway rat) | 0.2278 | |
| Kappa-type opioid receptor | Mus musculus (house mouse) | 0.0828 | |
| Mu-type opioid receptor | Rattus norvegicus (Norway rat) | 0.0385 | |
| Kappa-type opioid receptor | Rattus norvegicus (Norway rat) | 0.0545 | |
| Mu-type opioid receptor | Homo sapiens (human) | 0.122 | |
| Delta-type opioid receptor | Homo sapiens (human) | 0.1199 | |
| Kappa-type opioid receptor | Cavia porcellus (domestic guinea pig) | 0.9308 | |
| Kappa-type opioid receptor | Homo sapiens (human) | 0.655 | |
| Mu-type opioid receptor | Mus musculus (house mouse) | 0.3305 | |
| Mu-type opioid receptor | Cavia porcellus (domestic guinea pig) | 0.202 | |
| Beta-2 adrenergic receptor | Cavia porcellus (domestic guinea pig) | 0.25 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gudka, BD; Sirén, AL; Vonhof, S | 1 |
1 other study(ies) available for tyrosyl-arginyl-phenylalanyl-sarcosine and morphine
| Article | Year |
|---|---|
Tolerance and dependence following chronic intracerebroventricular infusions of Tyr-D-Arg2-Phe-Sar4 (TAPS).
Topics: Analgesics, Opioid; Animals; Dose-Response Relationship, Drug; Drug Tolerance; Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; In Vitro Techniques; Infusion Pumps; Injections, Intraventricular; Male; Morphine; Naloxone; Oligopeptides; Pain; Rats; Rats, Sprague-Dawley; Substance Withdrawal Syndrome; Substance-Related Disorders; Time Factors | 2003 |